Table of Contents

General Information	.S2
General Procedure for AROCM	.S4
Characterization Data for AROCM Products	.S6
Procedures and Characterization Data for (+)-endo Brevicomin Synthesis	326
Procedures and Characterization Data for L-Ribose Synthesis	330

General Information.

All reactions were carried out in dry glassware under an Argon atmosphere using standard Schlenk line techniques or in a Vacuum Atmospheres glovebox under nitrogen atmosphere. All solvents were purified by passage through solvent purification columns and further degassed with Argon.¹ NMR solvents for air-sensitive compounds were degassed by sparging with nitrogen and passed through a solvent purification column prior to use. Commercially available reagents were used as received unless otherwise noted. Substrates in the liquid state were degassed with Argon and passed through a plug of neutral alumina prior to use. Solid substrates were used after purification by silica gel column chromatography.

Standard NMR spectroscopy experiments were conducted on a Varian INOVA 500 (¹H: 500 MHz, ¹³C: 125 MHz) spectrometer. Chemical shifts are referenced to the residual solvent peak (CDCl₃) multiplicity is reported as follows: (s: singlet, d: doublet, t: triplet: q: quartet, br: broad, m: multiplet). Spectra were analyzed and processed using MestReNova.

Gas chromatography data was obtained using an Agilent 6850 FID gas chromatograph equipped with an Agilent HP-5 5% phenyl methyl siloxane capillary column (J&W Scientific). GC instrument conditions: Inlet temperature-250 °C; Detector temperature- 300 °C; Hydrogen flow- 30 mL/min; Air flow- 400

¹ A. B. Pangborn, M. A. Giardello, R. H. Grubbs, R. K. Rosen, F. J. Timmers, *Organometallics* **1996**, *15*, 1518-1520.

mL/min; Makeup flow- 25 mL/min. GC method: 50 °C for 1 min, then temperature ramp (35 °C/min) for 7 min to 300 °C followed by an isothermal period at 300 °C for 3 min. Chiral gas chromatography was carried out on an Agilent 6850 FID gas chromatograph equipped with an Agilent GTA column. GC instrument conditions: Inlet temperature- 180 °C; Detector temperature- 250 °C; Hydrogen flow- 32 mL/min; Air flow- 400 mL/min; Makeup flow- 30 mL/min. GC method: 80 °C for 12 min, isocratic.

High-resolution mass spectra (HRMS) data were obtained on a JEOL MSRoute mass spectrometer using FAB+ or EI+ methods. Analytical SFC data was obtained on a Mettler SFC supercritical CO₂ analytical chromatography system equipped with Chiracel OD-H, OJ–H or Chirapak AD-H columns (4.6 mm x 25 cm). Column temperature was maintained at 40°C. Optical rotations were measured on a Jasco P-2000 polarimeter using a 100 mm path-length cell at 589 nm.

Substrates for AROCM

Substrates for AROCM were synthesized as previously reported in the literature:

 $2^{2}, 5a^{3}, b^{3}, c^{4}, d^{5}$ were synthesized according to the provided references.

Catalyst **1** was synthesized as previously reported.⁶

² W. Kirmse, F. Scheidt, H-J. Vater, J. Am. Chem. Soc., **1978**, 100, 3945.

³ A. H. Hoveyda, P. J. Lombardi, R. V. O'Brien, A. R. Zhugralin, *J. Am. Chem. Soc.* **2009**, *131*, 8378.

⁴ R. Gandolfi, M. Ratti, L. Toma, C. De Micheli, *Heterocycles* **1979**, *12*, 897.

Representative Procedure for AROCM

In a glovebox, cyclobutene **2** (26.6 mg, 0.1 mmol, 1 equiv) and allyl benzoate (**6b**, 113 mg, 0.7 mmol, 7 equiv) were dissolved in 0.15 mL THF. To this solution was added 50 μ L of a stock solution (0.02 M in THF) of catalyst **1**. The reaction vial was capped and stirred for 1.5 h and then quenched with an excess of ethyl vinyl ether. The reaction mixture was concentrated and *Z*/*E* ratios were determined by 500 MHz ¹H NMR (products **7a-c**, **e-k**) or GC (product **4**). The crude was subjected to flash chromatography or preparative TLC to afford the desired AROCM product (**7f**, 25.9 mg, 61% isolated yield, 88:12 Z/E, 97% ee (*Z*), 88% ee (*E*)). Pure products (or *E*/*Z* mixtures in the case of **7i**, and *E*-**7j**) were submitted to analytical SFC to determine enantiomer excess.

Characterization data for AROCM products

Acetate 4.

79% yield (GC), 85% Z.

Z-4:

 $[\alpha]_D^{25} - 9.34^\circ$ (c = 0.52, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.24 (m, 10H), 5.88 – 5.77 (2x m, 1H), 5.71 – 5.64 (m, 1H), 5.34 (m, 1H), 5.29 (m, 1H), 4.64 (AB d, *J* = 10.5 Hz, 1H), 4.63 (AB d, *J* = 10.5 Hz, 1H), 4.61 (m, 1H), 4.51 – 4.46 (m, 1H), 4.45 (AB d, *J* = 10.5 Hz, 1H), 4.43 (AB d, *J* = 10.5 Hz, 1H), 4.21

⁵ A. H. Hoveyda, R. Khan, M. Kashif, P. J. Lombardi, R. V. O'Brien, S. Torker, A. R. Zhugralin, *J. Am. Chem. Soc.* **2012**, *134*, 12438.

⁶ J. Hartung, R. H. Grubbs, J. Am. Chem. Soc. **2013**, 135, 10183.

(ddd, J = 9.1, 5.0, 1.0 Hz, 1H), 3.87 (dd, J = 7.5, 5.0 Hz, 1H), 2.04 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 170.8, 138.6, 138.4, 135.5, 131.9, 128.5, 128.4, 128.4, 127.8, 127.7, 127.7, 127.5, 119.2, 82.2, 76.6, 70.7, 70.6, 60.8, 21.1. HRMS (FAB+) calculated for C₂₃H₂₇O₄ [M+H]: 367.1909; found 367.1904.

Separation conditions for Z-4: OJ-H, 5% IPA, 2.5 mL/min. 95% ee





Enantioenriched:



Signal 1: DAD1 A, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Туре	Width [min]	Area [mAU*s]	Height [mAU]	Area ۶
1	7.955	BV	0.2626	264.61841	14.94419	2.6277
2	10.319	BV	0.3029	9805.57031	456.01086	97.3723
Total	s:			1.00702e4	470.95505	

E-**4**:

[α]_D²⁵ – 11.8° (c = 0.24, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.24 (m, 10H), 5.88 – 5.74 (3x m, 1H), 5.33 (m, 1H), 5.29 (m, 1H), 4.65 (AB d, J = 9.3 Hz, 1H), 4.63 (AB d, 9.3 Hz, 1H), 4.61 (d, J = 6.0 Hz, 2H), 4.45 (AB d, J = 10.6 Hz, 1H), 4.43 (AB d, J = 10.7 Hz, 1H), 3.89 (dd, J = 6.4, 5.1 Hz, 1H), 3.85 (dd, J = 7.2, 5.1 Hz, 1H), 2.08 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 170.9, 138.41, 138.33, 135.5, 131.7, 128.46, 128.45, 128.40, 127.8, 127.75, 127.6, 127.55, 119.1, 82.4, 81.3, 70.9, 70.6, 64.4, 21.1. HRMS (FAB+) calculated for C₂₃H₂₇O₄ [M+H]: 367.1909; found 367.1922.

Separation conditions for *E*-**4**: OJ-H, 7% IPA, 2.5 mL/min. 85% ee

Racemate:



Enantioenriched:



Signal 1	: DAD1	Α,	Sig=210,8	Ref=360,100
----------	--------	----	-----------	-------------

Peak Re #	etTime [min]	Туре	Width [min]	Area [mAU*s]	Height [mAU]	Area ۴
1	7.842	BV	0.2188	764.89539	48.82001	7.2443
2	8.336	VB	0.2556	9793.63672	540.08466	92.7557
Totals	:			1.05585e4	588.90466	

Silyl ether **7a**.⁷

66% isolated yield, 88% Z.

Z-7a∶

[α]_D²⁵ + 4.72° (c = 1.06, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 5.84 (ddd, J = 17.3, 10.4, 6.4 Hz, 1H), 5.80 – 5.75 (m, 1H), 5.49 (dddd, J = 11.2, 8.9, 1.7, 1.1 Hz, 1H), 5.23 (ddd, J = 17.3, 1.8, 1.2 Hz, 1H), 5.16 (ddd, J = 10.4, 1.8, 1.0 Hz, 1H), 4.34 (ddd, J = 8.9, 7.0, 1.1 Hz, 1H), 4.15 (m, 2H), 3.90 (ddt, J = 7.3, 6.4, 1.1 Hz, 1H), 2.31 (br, 1H), 0.88 (s, 9H), 0.86 (s, 9H), 0.05 (s, 3H), 0.03 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 139.3, 134.4, 130.3, 116.5, 77.5, 72.8, 59.3, 26.1, 25.9, 18.5, 18.3, -4.2, -4.2, -4.3, -4.5. HRMS (EI+) calculated for C₁₉H₄₁O₃Si₂ [M+H]: 375.2594; found 375.2583.

Z-**7a** was derivatized by benzoylation and subsequent desilylation to afford a product spectroscopically identical to *Z*-**7b** prior to chiral SFC analysis, which indicated 99% ee (see directly below (p. S10) for racemic trace). Enantioenriched:

⁷ S. Saito, H. Itoh, Y. Ono, K. Nishioka, T. Moriwake, *Tetrahedron: Asymmetry* **1993**, *4*, 5.



Diol 7b.

67% isolated yield, 75% Z.

Z-7b:

[α]_D²⁵ – 30.7° (c = 0.60, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.06 – 8.01 (m, 2H), 7.60 – 7.54 (m, 1H), 7.47 – 7.41 (m, 2H), 5.89 (ddd, 17.3, 10.5, 6.2 Hz, 1H), 5.93 – 5.76 (2x m, 1H), 5.38 (ddd, J = 17.3, 1.5, 1.4 Hz, 1H), 5.28 (ddd, J = 10.6, 1.5, 1.4 Hz, 1H), 5.08 (ddd, J = 12.9, 7.7, 0.8 Hz, 1H), 4.83 (ddd, J = 12.6, 5.5, 1.0 Hz, 1H), 4.63 (dd, J = 8.0, 4.3 Hz, 1H), 4.25 (ddt, J = 6.8, 4.3, 1.3 Hz, 1H), 2.85 (br, 1H), 2.34 (br, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 166.9, 136.0, 133.3, 132.5, 130.0, 129.8, 128.6, 127.7, 118.0, 75.5, 70.4, 61.3. HRMS (EI+) calculated for C₁₄H₁₇O₄ [M+H]: 249.1127; found 249.1117.

Separation conditions for *Z*-**7b**: OD-H, 20% IPA, 2.5 mL/min. 91% ee Racemate:



Enantioenriched:



E-7b:

[α]_D²⁵ – 1.57° (c = 0.06, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.08 – 8.01 (m, 2H), 7.60 – 7.54 (m, 1H), 7.48 – 7.41 (m, 2H), 6.02 (dtd, J = 15.7, 5.7, 1.3 Hz, 1H), 5.96 – 5.77 (m, 2H), 5.37 (ddd, J = 17.3, 1.5, 1.4 Hz, 1H), 5.29 (ddd, J = 10.6, 1.5, 1.4 Hz, 1H), 5.07 (m, 1H), 4.87 (m, 1H), 4.68 (m, 1H), 4.25 (m, 1H), 2.89 (br, 1H), 2.00 (br, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 166.8, 135.9, 133.3, 132.5, 130.1, 129.8, 128.6, 127.9, 118.0, 75.6, 70.3, 61.2.

Separation conditions for E-7b: OJ-H, 20% IPA, 2.5 mL/min. 67% ee

Racemate:



Enantioenriched:



Benzoate 7c.

69% isolated yield, 75% Z.

Z-7c:

 $[\alpha]_D^{25}$ + 4.06° (c = 0.95, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.09 – 8.04 (m, 2H), 8.02 – 7.97 (m, 2H), 7.61 – 7.54 (2x m, 1H), 7.49 – 7.39 (2x m, 2H), 6.09 –

5.96 (3x m, 1H), 5.83 – 5.78 (m, 1H), 5.67 (dd, J = 11.0, 9.7 Hz, 1H), 5.52 (d, J = 17.3 Hz, 1H), 5.41 (d, J = 10.5 Hz, 1H), 4.56 (ddd, J = 13.4, 7.8, 1.4 Hz, 1H), 4.20 (ddd, J = 13.4, 5.7, 1.2 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 166.1, 165.6, 135.4, 133.5, 133.4, 131.8, 130.0, 129.9, 129.85, 129.80, 128.6, 128.6, 125.3, 120.4, 75.6, 71.4, 58.8. HRMS (FAB+) calculated for C₂₁H₂₁O₅ [M+H]: 353.1389; found 353.1381.

Separation conditions for Z-7c: OJ-H, 5% IPA, 2.5 mL/min. 96% ee

Racemate



Enantioenriched



Signal	1:	DAD1	Α,	Sig=210,8	Ref=360	,100
the second second			/			

Peak #	RetTime [min]	Туре	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.836	вв	0.2567	6250.97852	370.80807	97.9546
2	10.889	BB	0.2427	130.52478	6.96354	2.0454
Total	ls :			6381.50330	377.77162	

E-7c:

[α]_D²⁵ – 1.14° (c = 0.56, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.10 – 7.97 (2x m, 2H), 7.60 – 7.52 (2x m, 1H), 7.48 – 7.39 (2x m, 2H), 6.10 (ddd, 15.5, 4.9, 4.8 Hz, 1H), 6.02 (ddd, 17.3, 10.6, 6.4 Hz, 1H), 5.92 (dddd, 15.4, 6.9, 1.7, 1.6 Hz, 1H), 5.84 (m, 1H), 5.80 (m, 1H), 5.49 (d, J = 17.2 Hz, 1H), 5.39 (d, J = 10.5 Hz, 1H), 4.24 – 4.18 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 165.6, 165.5, 135.2, 133.3, 131.8, 130.1, 129.9, 128.6, 128.6, 124.4, 120.1, 75.7, 74.9, 62.8. HRMS (FAB+) calculated for C₂₁H₁₉O₄ [M–OH]: 335.1283; found 335.1271.

Separation conditions for E-7c: OJ-H, 5% IPA, 2.5 mL/min. 82% ee.





Enantioenriched



Alcohol 7e.

62% isolated yield, 89% Z.

Z-7e:

[α]_D²⁵ – 2.95° (c = 0.76, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.24 (m, 10H), 6.02 (ddd, *J* = 11.1, 6.9, 6.8 Hz, 1H), 5.83 (ddd, *J* = 17.6, 10.4, 7.5 Hz, 1H), 5.56 (dd, *J* = 11.5, 8.9 Hz, 1H), 5.39 (m, 1H), 5.37 – 5.32 (m, 1H), 4.64 (AB d, *J* = 10.5 Hz, 1H), 4.62 (AB d, *J* = 11.0 Hz, 1H), 4.42 (AB d, *J* = 12.1 Hz, 1H), 4.38 (AB d, *J* = 11.7 Hz, 1H), 4.21 (dd, *J* = 8.6, 7.4, 1.0 Hz, 1H), 4.07 – 3.93 (2x m, 1H), 3.78 (dd, *J* = 7.2, 7.0 Hz, 1H), 2.13 (br, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 138.2, 137.7, 135.8, 133.7, 131.6, 128.5, 128.4, 128.2, 127.9, 127.8, 127.7, 119.5, 81.5, 76.3, 70.8, 70.7, 58.5. HRMS (FAB+) calculated for C₂₁H₂₅O₃ [M+H]: 325.1804; found 325.1803.

Separation conditions for *Z*-**7e**: OJ-H, 10% IPA, 2.5 mL/min. 93% ee Racemate:



Enantioenriched:



E-7e:

[α]_D²⁵ – 2.93° (c = 0.30, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.23 (m, 10H), 5.93 – 5.79 (2x m, 1H), 5.71 (ddd, J = 15.7, 7.5, 7.3 Hz, 1H), 5.33 (m, 1H), 5.29 (m, 1H), 4.65 (AB d, J = 12.2 Hz, 1H), 4.62 (AB d, J = 12.2 Hz, 1H), 4.47 (AB d, J = 12.2 Hz, 1H), 4.43 (AB d, J = 12.1 Hz, 1H), 4.18 (m, 2H), 3.90 (dd, J = 7.9, 5.6 Hz, 1H), 3.86 (ddd, J = 7.4, 4.8, 0.9 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 138.7, 138.6, 135.6, 133.7, 128.8, 128.4, 127.9, 127.8, 127.6, 127.5, 119.0, 82.5, 81.6, 70.8, 70.7, 63.2. HRMS (FAB+) calculated for $C_{21}H_{25}O_3$ [M+H]: 325.1804; found 325.1812.

Separation conditions for E-7e: OJ-H, 10% IPA, 2.5 mL/min. 86% ee

Racemate:



Enantioenriched:



Benzoate 7f.

61% isolated yield, 88% Z.

Z-7f:

[α]_D²⁵ – 50.9° (c = 0.74, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.08 – 8.02 (m, 2H), 7.60 – 7.54 (m, 1H), 7.47 – 7.41 (m, 2H), 7.37 – 7.22 (m, 10H), 5.97 (dddd, J = 11.3, 7.8, 5.8, 1.1 Hz, 2H), 5.85 (ddd, J = 17.1, 10.5, 7.5 Hz, 1H), 5.73 (ddd, J = 10.7, 9.2, 1.5 Hz, 1H), 5.35 – 5.33 (m, 1H), 5.31 (m, 1H), 4.87 (ddd, J = 13.2,7.8, 1.4 Hz, 1H), 4.73 (ddd, J = 13.2, 5.8, 1.6 Hz, 2H), 4.68 (AB d, J = 12.2 Hz 1H), 4.64 (AB d, J = 12.1 Hz, 1H), 4.49 (AB d, J = 12.1 Hz, 1H), 4.44 (AB d, J = 12.2 Hz 12.2 Hz, 1H), 4.30 (ddd, J = 9.1, 5.0, 1.1 Hz, 2H), 3.90 (dd, J = 7.5, 5.0 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 166.4, 138.6, 138.4, 135.5, 133.1, 132.1, 130.2, 129.7, 128.55, 128.50, 128.45, 128.40, 127.8, 127.75, 127.70, 127.5, 119.2, 82.3, 76.7, 70.7, 70.7, 61.2. HRMS (FAB+) calculated for C₂₈H₂₉O₄ [M+H]: 429.2066; found 429.2056.

Separation conditions for *Z*-**7f**: OJ-H, 20% IPA, 2.5 mL/min. 97% ee Racemate:



Enantioenriched:



E-7f:

¹H NMR (500 MHz, CDCl₃) δ 8.08 – 8.04 (m, 2H), 7.61 – 7.54 (m, 1H), 7.45 (m, 2H), 7.36 – 7.21 (m, 10H), 5.98 – 5.79 (3x m, 1H), 5.34 (m, 1H), 5.29 (m, 1H), 4.87 (2x m, 1H), 4.64 (AB d, *J* = 12.0 Hz, 2H), 4.47 (AB d, *J* = 12.1 Hz, 1H), 4.43 (AB d, *J* = 12.1 Hz, 1H), 3.92 (dd, *J* = 6.8, 5.3 Hz, 1H), 3.87 (dd, *J* = 6.8, 5.5 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 166.4, 138.50, 138.42, 135.6, 133.1, 131.8, 130.1, 129.82, 129.80, 128.55, 128.52, 128.44, 128.36, 127.8, 127.60, 127.56, 119.1, 82.4, 81.3, 70.9, 70.6, 64.8.

Separation conditions for *E*-**7f**: OD-H, 20% IPA, 2.5 mL/min. 88% ee Racemate:



Signal 1: DAD1 A, Sig=210,8 Ref=360,100

Peak R #	etTime [min]	Туре	Width [min]	Area [mAU*s]	Height [mAU]	Area ۶
-		-				
1	5.665	BV	0.1888	5934.12598	478.10345	49.9106
2	6.250	VB	0.2143	5955.37939	428.19113	50.0894
Totals	:			1.18895e4	906.29459	

Enantioenriched:



Silyl ether 7g.

68% yield, 87% Z. Initial product mixture derivatized by treatment with TBAF (3 equiv) to aid in purification; isolated product is spectroscopically identical to

alcohol 7e (see above, p. S14).

Optical rotations and enantiopurity of derivatized products:

Derivative of *Z*-**7g**: $[\alpha]_D^{25} - 2.2^\circ$ (c = 0.61, CHCl₃)

89% ee

Enantioenriched:



Derivative of *E*-7g: $[\alpha]_D^{25} - 3.4^\circ$ (c = 0.31, CHCl₃)

77% ee

DAD1 A, Sig=210,8 Ref=360,100 (C:\CHEM32\...CINTOSH\CF02_101B_EXT 2013-08-16 16-50-04\1-JH-268BE-EEDET.D)



Benzyl ether 7h.

64% isolated yield, 86% Z.

Z-7h:

 $[\alpha]_{D}^{25} - 29.7^{\circ}$ (c = 0.66, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.36 - 7.23 (m, 10H), 5.91 (dddd, *J* = 11.4, 7.3, 5.4, 1.1 Hz, 1H), 5.83 (ddd, *J* = 17.2, 10.4, 7.6

Hz, 1H), 5.61 (dddd, J = 11.0, 9.2, 1.7, 1.6 Hz, 1H), 5.34 – 5.30 (m, 1H), 5.28 (m,

1H), 4.64 (AB d, J = 12.2 Hz, 1H), 4.61 (AB d, J = 12.1 Hz, 1H), 4.43 (AB d, J =

12.2 Hz, 1H), 4.43 – 4.41 (2x AB d, 1H), 4.40 (AB d, J = 12.1 Hz, 1H), 4.16 (ddd, J = 9.2, 4.9, 1.1 Hz, 1H), 4.04 (ddd, J = 12.6, 7.3, 1.6 Hz, 1H), 3.93 (ddd, J = 12.6, 5.4, 1.8 Hz, 1H), 3.82 (dddd, J = 7.6, 5.0, 1.2, 0.9 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 138.6, 138.5, 138.3, 135.5, 131.6, 130.3, 128.52, 128.39, 128.36, 127.84, 127.81, 127.77, 127.76, 127.56, 127.53, 119.1, 82.5, 76.4, 72.5, 70.6, 70.4, 66.4. HRMS (FAB+) calculated for C₂₈H₃₁O₃ [M+H]: 415.2273; found 415.2260.

Separation conditions for *Z*-**7h**: OD-H, 15% IPA, 2.5 mL/min. 91% ee Racemate:



```
Signal 1: DAD1 A, Sig=210,8 Ref=360,100
```

Peak	RetTime	Туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	90
1	7.714	BB	0.2523	3691.89014	233.73363	49.8466
2	8.793	VB	0.2827	3714.60791	205.71669	50.1534
Total	s:			7406.49805	439.45032	

Enantioenriched:



Signal 1: DAD1 A, Sig=210,8 Ref=360,100

Peak : #	RetTime [min]	Туре	Width [min]	Area [mAU*s]	Height [mAU]	Area ۶
1	7.739	BV	0.2524	6725.33252	416.38754	95.2967
2	8.821	VB	0.2569	331.92462	18.54005	4.7033
Total	s:			7057.25714	434.92760	

7i.

Isolated as an inseparable 9:1 Z/E mixture, 76% yield.

Z-**7**i: ¹H NMR (500 MHz, CDCl₃) δ 7.38 – 7.25 (m, 10H), 7.06 – 7.00 (m, 2H), 6.79 – 6.75 (m, 2H), 5.95 – 5.82 (2x m, 1H), 5.54 (ddd, *J* = 11.0, 9.4, 1.7, 1.5 Hz, 1H), 5.37 (m, 1H), 5.29 (m, 1H), 4.67 (2x AB d, *J* = 12.2 Hz, 2H), 4.49 (AB d, *J* = 12.2 Hz, 1H), 4.47 (AB d, *J* = 12.1 Hz, 1H), 4.36 (ddd, *J* = 9.3, 4.8, 1.1 Hz, 1H), 3.89 (dd, *J* = 7.7, 4.9 Hz, 1H), 3.78 (s, 3H), 3.34 – 3.20 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 158.0, 138.77, 138.76, 135.7, 133.9, 132.4, 129.63, 129.45, 128.4, 128.0, 127.84, 127.78, 127.53, 127.49, 119.0, 114.0, 82.7, 76.3, 70.6, 70.3, 55.4, 33.4. HRMS (FAB+) calculated for C₂₈H₃₁O₃ [M+H]: 415.2273; found 415.2287.

Separation conditions for *Z/E* product mixture: AD-H, 10% IPA, 2.5 mL/min. *Z*: 93% ee; *E*: 79% ee.





Didugi I. DUDI V' DIG-210'0 Mei-200'10	Signal	1:	DAD1	Α,	Sig=210,8	Ref=360,	,100
--	--------	----	------	----	-----------	----------	------

Peak RetTime Type	Width	Area	Height	Area
# [min]	[min]	[mAU*s]	[mAU]	%
1 9.466 VB	0.2176	4234.35059	305.74072	44.0459
2 10.421 BV	0.2378	4251.52734	279.00278	44.2245
3 10.869 VV	0.2464	545.18933	34.12083	5.6711
4 12.217 VV	0.2952	582.43701	31.58193	6.0585
Totals :	1	9613.50427	650.44626	

Enantioenriched:



```
Signal 1: DAD1 A, Sig=210,8 Ref=360,100
```

Peak	RetTime	туре	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	%
1	8.802	BV	0.2556	5 2.11839e4	1345.92456	85.3335
2	9.623	BV		3 735.39227	48.94960	2.9623
3	9.977	VB	0.2593	298.80161	16.18907	1.2036
4	11.232	BV	0.2637	2606.73169	152.29791	10.5005
Totals	з:			2.48248e4	1563.36114	

Ketone 7j.

65% isolated yield, 90% Z.

Z-7j:

[α]_D²⁵ – 7.98° (c = 1.35, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.39 – 7.22 (m, 10H), 5.86 (ddd, J = 17.2, 10.4, 7.6 Hz, 1H), 5.65 (dtd, J = 11.1, 7.5, 1.0 Hz, 1H), 5.46 (ddt, J = 10.9, 9.3, 1.6 Hz, 1H), 5.35 (m, 1H), 5.27 (m, 1H), 4.66 (AB d, J = 12.1 Hz, 1H), 4.61 (AB d, J = 12.2 Hz, 1H), 4.45 (AB d, J = 12.1 Hz, 1H), 4.43 (AB d, J = 12.2 Hz, 1H), 4.23 (ddd, J = 9.3, 5.0, 1.0 Hz, 1H), 3.84 (dd, J = 7.6, 5.0, 1H), 2.38 (m, 2H), 2.24 (m, 2H), 2.04 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 208.0, 138.753, 138.746, 135.7, 133.2, 128.6, 128.36, 128.34, 127.81, 127.75,

127.51, 127.49, 118.9, 82.6, 76.3, 70.6, 70.3, 43.3, 30.0, 22.3. HRMS (FAB+) calculated for $C_{24}H_{29}O_3$ [M+H]: 365.2117; found 365.2113.

Separation conditions for Z-7j: OJ-H, 5% IPA, 2.5 mL/min. 92% ee

Racemate



Enantioenriched



E/Z-7j mixture:



Signal 1: DAD1 A, Sig=210,8 Ref=360,100

Peak #	RetTime [min]	Туре	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	9.874	BB	0.2847	2521.13306	133.25986	16.6689
2	10.986	BV	0.3148	2570.48706	123.50429	16.9952
3	11.655	VB	0.3314	5003.31738	226.75299	33.0803
4	12.990	BB	0.3684	5029.84863	206.30301	33.2557
Total	ls :			1.51248e4	689.82014	

Enantioenriched: E 84% ee.



Boronic ester 7k.

50% isolated yield of Z product.

 $[\alpha]_{D}^{25} - 7.98^{\circ}$ (c = 0.64, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.28 (m,

10H), 5.94 – 5.78 (2x m, 1H), 5.43 (dddd, J = 11.0, 9.3, 1.7, 1.5 Hz, 1H), 5.28 (m,

1H), 5.25 (m, 1H), 4.67 (AB d, J = 12.2 Hz, 1H), 4.64 (AB d, J = 12.3 Hz, 1H),

4.47 (AB d, J = 12.4 Hz, 1H), 4.44 (AB d, J = 12.2 Hz, 1H), 4.30 (ddd, J = 9.4,

4.0, 1.1 Hz, 1H), 3.88 (dd, J = 7.7, 4.0 Hz, 1H), 1.69 (m, 2H), 1.23 (s, 6H), 1.22

(s, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 139.1, 139.0, 135.7, 130.0, 128.31, 128.30, 127.7, 127.6, 127.34, 127.33, 126.9, 118.8, 83.5, 82.8, 76.2, 70.5, 70.1, 24.94, 24.93. HRMS (FAB+) calculated for C₂₀H₂₈O₃B [M-OBn]: 327.2132; found 327.2138.

Separation conditions for Z-7k: OJ-H, 5% IPA, 2.5 mL/min. 91% ee

7404.02222 352.28293



Enantioenriched

Totals :

Racemate



Signal 1: DAD1 A, Sig=210,8 Ref=360,100

Peak	RetTime	Type	Width	Area	Height	Area
#	[min]		[min]	[mAU*s]	[mAU]	8
1	4.898	BV	0.1625	331.67175	30.59655	4.2149
2	5.190	VV	0.2376	402.79446	23.30932	5.1187
3	7.472	VV	0.2806	7134.57031	384.21341	90.6664
Total	s:			7869.03653	438.11928	

Synthesis of (+)-endo-brevicomin, 11

Alcohol 9.

Alcohol **9** was synthesized following the general AROCM procedure in 85% isolated yield, 91% Z, and 1:1 dr.

Z-9:

¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.24 (m, 10H), 5.89 – 5.78 (2x m, 1H), 5.54 – 5.43 (dddd, *J* = 11.1, 9.8, 1.3, 1.0 Hz, 1H), 5.38 (m, 1H), 5.32 (m, 1H), 4.66 (AB d, *J* = 12.3 Hz, 2H), 4.59 (AB d, *J* = 12.2 Hz, 2H), 4.41 (AB d, *J* = 12.4 Hz, 2H), 4.38 (AB d, *J* = 12.1 Hz, 2H), 4.20 (ddd, *J* = 9.8, 6.9, 0.9 Hz, 2H), 3.78 (dd, *J* = 7.7, 6.9 Hz, 1H), 3.74 (m, 1H), 2.81 (br, 1H), 2.18 – 2.10 (m, 2H), 1.16 (d, *J* = 6.2 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 138.5, 137.9, 135.9, 131.8, 131.1, 128.40, 128.37, 128.2, 127.82, 127.75, 127.6, 119.7, 81.2, 75.6, 70.23, 70.18, 66.9, 38.1, 23.2. HRMS (FAB+) calculated for C₂₃H₂₉O₃ [M+H]: 353.2117; found 353.2108.

Ketone 10:

Dess-Martin periodinane (302 mg, 0.713 mmol, 2 equiv) was added in one portion to a cold (0°C) solution of alcohols *Z*-**9** (126 mg, 0.356 mmol) in CH₂Cl₂ (5 mL). The reaction mixture was allowed to warm to room temperature and stirred for 1 h. Aqueous 1:1 NaHCO₃/ Na₂S₂O₃ solution was added and the biphasic mixture stirred vigorously for 1 h. The layers were separated, and the aqueous layer extracted with CH₂Cl₂. The combined organic layers were dried over

S26

MgSO₄, filtered and concentrated. The crude residue was purified by flash chromatography to afford 110.4 mg, 88% yield of ketone **10**.

[α]_D²⁵ – 14.4° (c = 0.83, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.36 – 7.24 (m, 10H), 5.93 (dddd, *J* = 11.1, 10.8, 7.2, 1.1 Hz, 1H), 5.85 (ddd, *J* = 17.2, 10.4, 7.6 Hz, 1H), 5.63 (dddd, *J* = 11.0, 9.1, 1.7, 1.4 Hz, 1H), 5.36 – 5.33 (m, 1H), 5.33 – 5.27 (m, 1H), 4.63 (2x ABd, *J* = 12.0 Hz, 2H), 4.43 (AB d, *J* = 10.8 Hz, 1H), 4.39 (AB d, *J* = Hz, 1H), 4.09 (ddd, *J* = 9.1, 5.2, 1.1 Hz, 1H), 3.84 (dd, *J* = 7.6, 5.3 Hz, 1H), 3.08 (dd, *J* = 7.2, 1.7 Hz, 2H), 2.03 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 206.1, 138.6, 138.4, 135.6, 130.7, 128.40, 128.37, 127.87, 127.86, 127.62, 127.58, 126.4, 119.1, 82.4, 76.3, 70.7, 70.3, 42.7, 29.8. HRMS (FAB+) calculated for C₂₃H₂₇O₃ [M+H]: 351.1960; found 351.1954.

Separation conditions for 10: AD-H, 5% IPA, 2.5 mL/min. 95% ee





Enantioenriched:



(+)-endo-brevicomin (11).

Ketone **10** (35 mg, 0.10 mmol) was dissolved in 5:1 MeOH/1 N HCl (aq.) and the reaction flask purged with Argon. Palladium on carbon (10%, 35 mg) was added, and the flask was purged by a balloon filled with H₂. The reaction mixture was stirred under 1 atm of H₂ for 2 h. The reaction flask was then purged with Argon and Celite was added. The suspension was filtered through Celite and the organic layer was extracted with pentane. The combined pentane layers were washed with water, brine, and dried over MgSO₄. The pentane layers were filtered and carefully concentrated to afford the crude reaction mixture (9.9 mg, 67% yield), containing 90% purity (+)-*endo*-brevicomin. Analytical samples were afforded by flash chromatography.

 $[\alpha]_{D}^{25} + 49.6^{\circ}$ (c = 0.11, CHCl₃), lit.⁸ $[\alpha]_{D}^{20} + 49^{\circ}$ (c = 1.0, ether, 96.5% ee, 90% purity), lit.⁹ $[\alpha]_{D}^{20} + 77.9^{\circ}$ (c = 1.2, ether, 99.3% ee); ¹H NMR (500 MHz, CDCl₃) δ 4.21 (dt, *J* = 4.6, 2.3 Hz, 1H), 3.99 (tdd, *J* = 7.2, 4.1, 1.0 Hz, 1H), 1.99 - 1.72 (m,

⁸ G. Pedrocchi-Fantoni, S. Servi, J. Chem. Soc., Perkin. Trans. 1 **1991**, 1764.

⁹ S. Singh, P. J. Guiry, J. Org. Chem. **2009**, 74, 5758.

4H), 1.68 – 1.51 (m, 4H), 1.43 (s, 3H), 0.99 (t, J = 7.5 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 107.0, 81.6, 76.6, 34.4, 25.0, 23.6, 21.9, 17.6, 10.9. HRMS (FAB+) calculated for C₉H₁₇O₂ [M+H]: 157.1229; found 157.1206. Separation conditions (GC, GTA column): 80°C, isocratic. 96% ee





Enantioenriched:



Synthesis of ribose derivative 13

Diol **12**.

To a biphasic mixture of 1:1 tBuOH/water containing diene *Z*-**7g** (38.5 mg, 0.089 mmol) was sequentially added potassium carbonate (37 mg, 0.27 mmol), potassium ferricyanide (89 mg, 0.27 mmol, 3 equiv), and potassium osmate dihydrate (1.7 mg, 4.6 µmol, 5 mol%) at 0°C. The reaction was stirred vigorously at 23°C for 24 h. Upon completion, solid Na₂SO₃ was added stirred continued at 23°C for 2 h. EtOAc was added and the layers separated. The aqueous layer was extracted with EtOAc and the combined organic layers washed with water, brine, and dried over MgSO₄. After filtration and concentration, the crude residue was subject to flash chromatography to afford 27.5 mg, 66% yield of diol **12**. Major diastereomer:

[α]_D²⁵ – 62.1° (c = 1.35, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.05 – 8.01 (m, 2H), 7.60 – 7.55 (m, 1H), 7.44 (dd, J = 8.5, 7.2 Hz, 2H), 7.37 – 7.22 (m, 26H), 6.05 – 5.97 (m, 1H), 5.86 – 5.78 (m, 1H), 4.89 – 4.83 (m, 2H), 4.77 (d, J = 11.1 Hz, 1H), 4.67 (d, J = 11.8 Hz, 1H), 4.65 – 4.62 (m, 1H), 4.60 (dd, J = 9.6, 4.6 Hz, 1H), 4.45 (d, J = 11.7 Hz, 1H), 3.72 (dt, J = 13.1, 5.0 Hz, 4H). ¹³C NMR (125 MHz, CDCl₃) δ 166.6, 138.1, 137.8, 133.3, 131.3, 129.87, 128.78, 128.65, 128.62, 128.58, 128.3, 128.02, 128.01, 128.0, 80.9, 76.1, 74.6, 72.1, 70.8, 66.3, 63.7, 61.2. HRMS (FAB+) calculated for C₂₈H₃₁O₆ [M+H]: 463.2121; found 463.2125. Methyl glycoside **13**.

Diol 12 (34.6 mg, 0.075 mmol) was dissolved in 1:1 CH₂Cl₂/MeOH and cooled to -78°C. Ozone was bubbled through the solution until a blue color persisted for 10 min. At this point, oxygen was bubbled through the solution until the reaction appeared colorless. Excess dimethyl sulfide (0.1 mL) was added and the reaction was allowed to come to room temperature and stir for 16 h. The reaction mixture was concentrated and the crude residue used in the following step. The crude aldehyde was then dissolved in MeOH (5 mL) and cooled to 0°C. HCl in MeOH (0.4 M, 0.5 mL) was added and the reaction was warmed to room temperature. The reaction was stirred for 14 h, at which time Amberlyst IRA-400 (OH⁻) was added. The mixture was filtered and concentrated; preparative TLC afforded 10.6 mg (0.031 mmol, 47% yield over two steps) of methyl glycoside 13. $[\alpha]_{D}^{25} = -36.4^{\circ}$ (c = 0.27, CHCl₃), lit.¹⁰ ent-13 $[\alpha]_{D}^{25} = +31.7$ (c = 1.94, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.40 – 7.27 (m, 10H), 4.89 (s, 1H), 4.66 (AB d, J = 12.0 Hz, 1H), 4.63 (AB d, J = 12.0 Hz, 1H), 4.58 (AB d, J = 11.7 Hz, 1H), 4.49 (AB d, J = 11.7 Hz, 1H), 4.28 (m, 1H), 4.13 (dd, J = 7.1, 4.7 Hz, 1H), 3.87 (d, J = 11.7 Hz, 1H), 3.4.7 Hz, 1H), 3.83 – 3.77 (m, 1H), 3.58 (m, 1H), 3.37 (s, 3H), 1.95 (br, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 137.81, 137.79, 128.6, 128.1 (4C), 128.04 (3C), 128.00 (3C), 107.0, 82.4, 80.3, 77.4, 72.8, 72.6, 62.8, 55.7. HRMS (FAB+) calculated for C₂₀H₂₃O₅ [M+H-H₂]: 343.1545; found 343.1553.

¹⁰ P. A. Wender, F. C. Bi, N. Buschmann, F. Gosselin, C. Kan, J-M. Kee, H. Ohmura, *Org. Lett.* **2006**, *8*, 5373.



Figure S3. ¹H NMR (500 MHz, $CDCl_3$) of *E*-**4**.



Figure S4. ¹³C NMR (125 MHz, CDCl₃) of E-**4**.

PBQTQNQh ~	ЬG	ഗ	4	4 M	ഹ	4	4 (n n	n m	\sim	\sim	\sim	<u>-</u> ,						ი	б	\sim		9	ı و	_ ∠	1 4		\sim	\sim	\sim	\sim	л <i>и</i>	v C	0	\sim	∞	9	9	4 (⊃ ∝	പ	n m
	<u>ب</u>	14	4	4.4	- m	e.	ς Ω	'n	$\cdot \cdot \cdot$	m.	e.	Ċ.	m i	m d	γi	γin	ņο	ο u	i vi	~	2	2	~	2.0	νi	о ч	i wi	Ċ.	ς.	m.	n in	۰v	ο u	jω	∞	9	9	و	٩	o'⊿	14	. 4
	ή~ г	< r	\sim	ファ	- ^-	\sim	r /1	<u>~ г</u>	~ ^	~	\sim	~		^ 1	~ 1	<u>~ г</u>	~ r	< r	- ~	\sim	\sim	\sim	\sim	r ∕1	 □ 	പ	ഹ	Ь	Ъ	ഹ	പപ	പ	പ	പ	4	4	4	4	4,	4 4	- 4	. 4
					_	_	<u> </u>	1 -		_												_	_																			







Figure S20. ¹³C NMR (125 MHz, CDCl₃) of *Z*-**7f**.








PBOTONOL	\sim	\sim	\sim	\sim			0	0	б	6) co	∞) co	9	\sim	-	-	\sim	9	9	و	0	0	00	ω		~ 0	و	m i	m r	n n	പ	\sim	n m	-	\sim	0	б	\sim	m		v,		- 0	⊃ ~	0	∞	\sim
101177990	\sim		\sim		\sim	0	0	0	8 S	Ь	Ь	Ь	4	4	∞	m	m	m	\sim	∞	m	$\sim \circ$	പെട	o o	9	9	4	4	\sim	\sim	\sim	$\sim c$	2	$\sim \sim$	2 (V C	> ∞	\sim	\sim									
Product (Z)	~	~	~	~	~	~	~	~	~	~	~	. ~	. ~	~	<u>ن</u>		<u>ن</u>	Ь.	ы.	Ь.	Ь.	Ь.	<u>ю</u> .	പ്	പ്	പ്	പ്പ	<u>ю</u> .	പ്	പ്പ	പ്പ	. 4	. 4	4	4.	4.	4.	4.	4.	4.	4. 4	÷.	4. ~	. .	. 4	:	щ.	с.
				-				-		L		\checkmark			<u> </u>		5	<u> </u>	~ ~	+	1	_			-				-			i i	i	i	i	Ĩ	Ĩ	-i	Ĩ	-i	i	i –	i	i	<u>i i</u>			



Figure S15. ¹H NMR (500 MHz, $CDCl_3$) of Z-**7e**.



Figure S16. ¹³C NMR (125 MHz, CDCl₃) of *Z*-**7e**.



Figure S17. ¹H NMR (500 MHz, $CDCl_3$) of *E*-**7e**.



Figure S18. ¹³C NMR (125 MHz, CDCl₃) of *E*-**7e**.



Figure S23. ¹H NMR (500 MHz, $CDCl_3$) of Z-**7g**.



Figure S24. ¹H NMR (500 MHz, $CDCl_3$) of Z-**7h**.



Figure S25. ¹³C NMR (125 MHz, CDCl₃) of Z-**7h**.



Figure S26. ¹H NMR (500 MHz, CDCl₃) of **7i**.



Figure S27. ¹³C NMR (125 MHz, CDCl₃) of **7i**.



Figure S11. ¹H NMR (500 MHz, $CDCl_3$) of Z-**7c**.



Figure S12. ¹³C NMR (125 MHz, CDCl₃) of *Z*-**7c**.



Figure S7. ¹H NMR (500 MHz, $CDCI_3$) of Z-**7b**.



Figure S8. ¹³C NMR (125 MHz, CDCl₃) of *Z*-**7b**.



Figure S9. ¹H NMR (500 MHz, $CDCl_3$) of *E*-**7b**.



Figure S5. ¹H NMR (500 MHz, CDCl₃) of Z-**7a**.



Figure S6. ¹³C NMR (125 MHz, CDCl₃) of Z-**7a**.



Figure S32. ¹H NMR (500 MHz, $CDCl_3$) of Z-**9**.



Figure S33. ¹³C NMR (125 MHz, CDCl₃) of *Z*-**9**.



Figure S34. 1 H NMR (500 MHz, CDCl₃) of **10**.



Figure S35. 13 C NMR (125 MHz, CDCl₃) of **10**.







Figure S38. 1 H NMR (500 MHz, CDCl₃) of **12**.



Figure S39. 13 C NMR (125 MHz, CDCl₃) of **12**.







Figure S41. ¹³C NMR (125 MHz, CDCl₃) of **13**.



Figure S13. ¹H NMR (500 MHz, CDCl₃) of E-**7c**.



Figure S14. ¹³C NMR (125 MHz, CDCl₃) of *E*-**7c**.



Figure S28. ¹H NMR (500 MHz, CDCl₃) of Z-**7**j.



Figure S29. ¹³C NMR (125 MHz, CDCl₃) of *Z*-**7**j.



Figure S30. ¹H NMR (500 MHz, CDCl₃) of Z-**7k**.



Figure S31. ¹³C NMR (125 MHz, CDCl₃) of Z-**7k**.



Figure S10. ¹³C NMR (125 MHz, CDCl₃) of *E*-**7b**.











